LBBW raises target for Gerresheimer stock to EUR 29.00

Published on 10/13/2026 at 13:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted EBITDA reached EUR 102.00 million versus EUR 67.00 million in the second quarter. Gerresheimer stock costs EUR 29.04 on October 13, 2026, minus 0.21 percent versus Xetra.

LBBW lifted its Gerresheimer target from EUR 28.00 to EUR 29.00 and kept a Hold rating on October 6, 2026.
Adjusted EBITDA reached EUR 102.00 million in the second quarter of 2026, up from EUR 67.00 million in the first quarter.
Gerresheimer stock traded at EUR 29.04 at Lang & Schwarz on October 13, 2026 at 1:45 p.m. CEST, minus 0.21 percent versus the Xetra close of October 12, 2026.
The half-year report is expected in late November 2026, while the price-to-earnings ratio stood at minus 2.50.

Bauhaus-Poster mit geometrischen Glasfläschchen und Schriftzug PHARMA — Gerresheimer AG, ISIN DE000A0LD6E6, inspiriert dieses geometrische Bauhaus-Poster mit stilisierten Glasfläschchen und dem Wort PHARMA, Illustration mit AI erstellt.

LBBW raised its price target for Gerresheimer from EUR 28.00 to EUR 29.00 and retained its Hold rating on October 6, 2026, according to Goldesel. The new target sits EUR 0.04 below the Lang & Schwarz price, a gap of 0.14 percent based on the current euro quote. Gerresheimer was trading at EUR 29.04 at Lang & Schwarz on October 13, 2026 at 1:45 p.m. CEST, minus 0.21 percent versus the Xetra close of October 12, 2026 at EUR 29.10.

Adjusted EBITDA recovers quarter over quarter

Gerresheimer's preliminary second-quarter 2026 results showed adjusted EBITDA of EUR 102.00 million, up from EUR 67.00 million in the first quarter of 2026. The company reported revenue of EUR 578.00 million for the second quarter, while first-half revenue reached EUR 1.10 billion compared with EUR 1.14 billion in the first half of 2025.

According to EQS News on September 30, 2026, the adjusted EBITDA margin improved to 17.60 percent in the second quarter from 12.60 percent in the first quarter. The same release reported a first-half adjusted EBITDA margin of 15.30 percent, below 19.60 percent in the prior-year period.

Stock remains below its yearly high

The Lang & Schwarz bid was EUR 28.96 and the ask was EUR 29.12 at 1:45 p.m. CEST on October 13, 2026. Trading volume on the primary German listing stood at 15,261 shares, compared with an average volume of 152,611 shares.

The 52-week range was EUR 14.83 to EUR 32.00 on October 13, 2026. At EUR 29.04, the stock was 9.25 percent below its 52-week high, leaving the current quote materially above its yearly low.

Valuation and November dates

Gerresheimer's market capitalization was EUR 1.0 billion on October 13, 2026, while its price-to-earnings ratio was minus 2.50. The investor-relations calendar lists the half-year financial report for late November 2026 and the third-quarter statement for November 2026, according to Gerresheimer.

Comparison with peers

Gerresheimer: minus 0.21 percent, price-to-earnings ratio minus 2.50, market capitalization EUR 1.0 billion
Stevanato Group (USD): minus 0.82 percent, price-to-earnings ratio 35.81, market capitalization USD 5.3 billion
SCHOTT Pharma (EUR): minus 0.83 percent, price-to-earnings ratio 26.26, market capitalization EUR 3.6 billion

Price and investor calendar

LBBW's EUR 29.00 target is close to the current quote, while the next major scheduled company information is expected in November 2026. The operating comparison is mixed: second-quarter adjusted EBITDA improved by EUR 35.00 million from the first quarter, but first-half revenue fell EUR 40.00 million year over year.

The further course of trading is shown by the continuously updated real-time quote of Gerresheimer stock.